Monday, 26 September 2016

2 Rounds of Lemtrada Seen to Effectively Treat MS Relapses for Years

ECTRIMS Multiple Sclerosis News Today:

Lemtrada (alemtuzumab) as a first treatment option for relapsing multiple sclerosis (MS) patients reduced relapse rates and disability progression throughout a study period of six years — although most patients received treatment only in the first two years. The study showed that Lemtrada has the potential to harness disease activity in the long run.  Read on.